Ixabepilone: Providing new hope for women with breast cancer after anthracycline and taxane failure

Clinical Journal of Oncology Nursing

Volumn 14, Issue 1, 2010, Pages 65-71

  Stein, Alisha ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; EPOTHILONE DERIVATIVE; FLUOROURACIL; IXABEPILONE; TAXOID; TUBULIN MODULATOR;

BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; HUMAN; PERIPHERAL NEUROPATHY; REVIEW;

ANTHRACYCLINES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; TAXOIDS; TUBULIN MODULATORS;

EID: 79952115874     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.65-71     Document Type: Article

References (48)

1. Abraham, J., Agrawal, M., Bakke, S., Rutt, A., Edgerly, M., Balis, F.M., Fojo, T. (2003). Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. Journal of Clinical Oncology, 21, 1866-1873. doi: 10.1200/JCO.2003.03.063
2. American Cancer Society. (2008). Statistics for 2008. Retrieved from http://www.cancer.org/docroot/stt/stt_0.asp?from=fast
3. Armstrong, T., Almadrones, L., & Gilbert, M.R. (2005). Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 32, 305-311. doi: 10.1188/05.ONF.305-311
4. Awada, A., Piccart, M.J., Jones, S.F., Peck, R.A., Gil, T., Lebwohl, D., Burris, H.A., III. (2008). Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemotherapy and Pharmacology, 63, 417-425. doi: 10.1007/s00280-008-0751-5
5. Blum, J., Dieras, V., Lo Russo, P., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001). Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 92, 1759-1768. doi: 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A
6. Boehnke Michaud, L. (2009). The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. Journal of Oncology Pharmacy Practice, 15, 95-106. doi: 10.1177/1078155208100095
7. Bristol-Myers Squibb. (2009). Ixempra® (ixabepilone) [Prescribing information]. Princeton, NJ: Author
8. Bunnell, C., Klimovsky, J., & Thomas, E. (2006). Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline [Abstract 10511]. Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=34400.
9. Cleator, S., Heller, W., & Coombes, R. (2007). Triple-negative breast cancer: Therapeutic options. Lancet Oncology, 8, 235-244.
10. Conlin, A.K., D'Andrea, G., Hudis, C.A., Robson, M.E., Drullinsky, P., Theodoulou, M., Seidman, A.D. (2008). Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT) [Abstract 1086]. Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31362.
11. Cortes, J., & Baselga, J. (2007). Targeting the microtubules in breast cancer beyond taxanes: The epothilones. Oncologist, 12, 271-280. doi: 10.1634/theoncologist.12-3-271
12. Denduluri, N., Low, J.A., Lee, J., Walshe, J.M., Vatas, U., Chow, C.K., Swain, S.M. (2007). Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. Journal of Clinical Oncology, 25, 3421-3427. doi: 10.1200/JCO.2006.10.0784
13. Fumoleau, P., Largillier, R., Clippe, C., Dieras, V., Orfeuvre, H., Lesimple, T., Namer, M. (2004). Multicentre, phase II study evaluating monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. European Journal of Cancer, 40, 536-542. doi: 10.1016/j.ejca.2003.11.007
14. Genentech, Inc. (2008). Herceptin® (trastuzumab) [Prescribing information]. San Francisco, CA: Author.
15. Genentech, Inc. (2010a). VEGF inhibition summary. Retrieved from http://www.avastin.com/avastin/hcp/overview/moa/targeting-vegf/index.m
16. Genentech, Inc. (2010b). What is HER2? Retrieved from http://www.herceptin.com/her2-breast-cancer/testing-education/what-is.jsp
17. Gianni, L. (2007). Ixabepilone and the narrow path to developing new cytotoxic drugs. Journal of Clinical Oncology, 25, 3389-3391.
18. GlaxoSmithKline. (2008). Tykerb® (lapatinib) [Prescribing information]. Retrieved from http://www.fda.gov/cder/foi/label/2008/022059s004lbl.pdf
19. Goodin, S., Kane, M.P., & Rubin, E.H. (2004). Epothilones: Mechanism of action and biologic activity. Journal of Clinical Oncology, 22, 2015-2025. doi: 10.1200/JCO.2004.12.001
20. Hoffmann, J., Vitale, I., Buchmann, B., Galluzzi, L., Schwede, W., Senovilla, L., Kroemer, G. (2008). Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Research, 68, 5301-5318. doi: 10.1158/0008-5472.CAN-08-0237
21. Hortobagyi, G.N. (1998). Treatment of breast cancer. New England Journal of Medicine, 339, 974-984.
22. Hortobagyi, G.N., Perez, E., Vrdoljak, E., Medina, C., Xu, B., Conte, P., Sparano, J.A. (2008, September). Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: Results from two randomized phase III trials. Presented at the American Society for Clinical Oncology Breast Cancer Symposium, Washington, DC.
23. Lee, F.Y.F., Borzilleri, R., Fairchild, C.R., Kim, S.H., Long, B.H., Reventos-Suarez, C., Kramer, R.A. (2001). BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clinical Cancer Research, 7, 1429-1437.
24. Lee, F.Y.F., Smykla, R., Johnston, K., Menard, K., McGlinchey, K., Peterson, R.W.,Kramer, R. (2009). Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemotherapy Pharmacology, 63, 201-212. doi: 10.1007/s00280-008-0727-5.
25. Lee, J., Low, J., Croarkin, E., Parks, R., Berman, A.W., Mannan, N., Swain, S.M. (2006). Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. Journal of Clinical Oncology, 1, 2084-2091. doi: 10.1200/JCO.2005.04.2820
26. Lee, J., & Swain, S. (2006). Peripheral neuropathy induced by microtubule-stabilizing agents. Journal of Clinical Oncology, 24, 1633-1642. doi: 10.1200/JCO.2005.04.0543
27. Longley, D., & Johnston, P. (2005). Molecular mechanisms of drug resistance. Journal of Pathology, 205, 275-292.
28. Love, N. (2008). Management of breast cancer in the adjuvant and metastatic settings. Retrieved from http://www.patternsofcare.com/breast/2008/1/pdf/POCB1_08.pdf
29. Low, J., Wedam, S., Lee, J., Berman, A.W., Brufsky, A., Yang, S.X., Swain, S.M. (2005). Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology, 23, 2726-2734. doi: 10.1200/JCO.2005.10.024
30. Markman, M. (2003). Management of toxicities associated with the administration of taxanes. Expert Opinion on Drug Safety, 2, 141-146. doi: 10.1517/14740338.2.2.141
31. Marsé, H., Van Cutsem, E., Grothey, A., & Valverde, S. (2004). Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). European Journal of Oncology Nursing, 8(1, Suppl.), S16-S30.
32. Monoclonal antibody approved for metastatic breast cancer. (1998). Oncology (Williston Park), 12, 1727.
33. Morrow, P.H., Divers, S.G., Provencher, L., Luoh, S., Petrella, T.M., Giurescu, M., Vahdat, L.T. (2009). Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC) [Abstract 1083]. Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35389.
34. National Comprehensive Cancer Network. (2010). NCCN Clinical Practice Guidelines in Oncology™: Breast cancer [v.1.2010]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
35. Perez, E., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L.,Hortobagyi, G.N. (2007). Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Journal of Clinical Oncology, 25, 3407-3414.
36. Perez, E., Pivot, X., Vrdoljak, E., Sparano, J.A., Vogel, C., Peck, R., Vahdat, L. (2008, December). A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: Data from a large registrational program in patients with metastatic breast cancer [No. 6140]. Poster presented at the San Antonio Breast Cancer Symposium, San Antonio, TX.
37. Reichardt, P., Von Minckwitz, G., Thuss-Patience, P., Jonat, W., Kolbl, H., Janicke, F., Luck, J. (2003). Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Annals of Oncology, 14, 1227-1233. doi: 10.1093/annonc/mdg346
38. Rivera, E., Lee, J., & Davies, A. (2008). Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist, 13, 1207-1223. doi: 10.1634/theoncologist.2008-0143
39. Roché, H., Yelle, L., Cognetti, F., Mauriac, L., Bunnell, C., Sparano, J., Cure, H. (2007). Phase II clinical trial of ixabepilone (bms-247550), an epothilone b analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. Journal of Clinical Oncology, 25, 3415-3420. doi: 10.1200/JCO.2006.09.7535
40. Rowinsky, E., & Calvo, E. (2006). Novel agents that target tublin and related elements. Seminars in Oncology, 33, 421-435. doi: 10.1053/j.seminoncol.2006.04.006
41. Rowinsky, E., Eisenhauer, E., Chaudhry, V., Arbuck, S., & Donehower, R. (1993). Clinical toxicities encountered with paclitaxel (Taxol). Seminars in Oncology, 20, 1-15.
42. Rubin, E.H., Rothermel, J., Tesfaye, F., Chen, T., Hubert, M., Ho, Y.Y., Oza, A.M. (2005). Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. Journal of Clinical Oncology, 23, 9120-9129.
43. Schmid, P., Kiewe, P., Kuehnhardt, D., Korfel, A., Lindemann, S., Giurescu, M., Possinger, K. (2005). A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors [Abstract 2051]. Retrieved from http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/2051
44. Surveillance Epidemiology and End Results. (2009). SEER stat fact sheets-Cancer of the breast. Retrieved from http://seer.cancer.gov/statfacts/html/breast.html
45. Thomas, E., Gomez, H.L., Li, R.K., Chung, H.C., Fein, L.E., Chan, V.F., Roche, H.H. (2007). Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Journal of Clinical Oncology, 25, 5210-5217.
46. Thomas, E., Tabernero, J., Fornier, M., Conte, P., Fumoleau, P., Lluch, A., Martin, M. (2007). Phase II clinical trial of ixabepilone (bms-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. Journal of Clinical Oncology, 25, 3399-3406.doi: 10.1200/JCO.2006.08.9102
47. Vahdat, L., Klimovsky, J., & Bunnell, C. (2006). Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: Final safety data [Abstract 10528]. Retrieved from http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/10528
48. Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing, 11, 361-376. doi: 10.1188/07.CJON.361-376